Publication
High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.
Authors not recorded
Clin Cancer Res2022PMID 34593528stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugLucitanibcivic_curation1.00
- drugRogaratinibcivic_curation1.00
- geneFGFR1civic_curation1.00
- variantFGFR1 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 34593528
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR1 Amplification1 | ||||||||
| Lucitanib + RogaratinibSubstitutes | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID12505FGFR1 amplification (FGFR1amp) is frequently detected in metastatic breast cancer (MBC), where it is recognized as a generic marker of poor prognosis and most notably, resistance to CDK4/6 inhibitors … (full text at CIViC) PMID 34593528 · Sánchez-Guixé et al., 2022 · Open in CIViC | civic |